TipRanks
Advertisement
Advertisement
HUTCHMED Stock (HCM) Rallies Over 15% on a Major Licensing Deal
PremiumMarket NewsHUTCHMED Stock (HCM) Rallies Over 15% on a Major Licensing Deal
15d ago
Hutchmed, GSK enter HMPL-A830 commercialization agreement
Premium
The Fly
Hutchmed, GSK enter HMPL-A830 commercialization agreement
16d ago
Hutchmed announces results from Saffron Phase III trial of Orpathys, Tagrisso
Premium
The Fly
Hutchmed announces results from Saffron Phase III trial of Orpathys, Tagrisso
1M ago
Hutchmed Moves HMPL-760 Forward With Food-Effect Study, Signaling Steady Pipeline Progress
PremiumCompany AnnouncementsHutchmed Moves HMPL-760 Forward With Food-Effect Study, Signaling Steady Pipeline Progress
3M ago
Hutchmed upgraded to Equal Weight from Underweight at Morgan Stanley
Premium
The Fly
Hutchmed upgraded to Equal Weight from Underweight at Morgan Stanley
4M ago
Hutchmed’s New HER2 Trial Adds Early Stage Upside to Its Oncology Pipeline
Premium
Company Announcements
Hutchmed’s New HER2 Trial Adds Early Stage Upside to Its Oncology Pipeline
4M ago
Hutchmed price target lowered to $20 from $21 at BofA
PremiumThe FlyHutchmed price target lowered to $20 from $21 at BofA
6M ago
Hutchmed discontinues all active tazemetostat clinical trials
Premium
The Fly
Hutchmed discontinues all active tazemetostat clinical trials
6M ago
Hutchmed price target lowered to $21 from $22 at BofA
Premium
The Fly
Hutchmed price target lowered to $21 from $22 at BofA
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100